Antibiotics

Latest News


Video Series


Latest Videos


Shorts

Antibiogram Use at the Bedside
0:57
Antibiogram Use at the Bedside
a month ago
by
Zachary Nelson, PharmD, MPH, BCIDP(+1 more)
Utilizing the New UTI Classifications
1:06
Utilizing the New UTI Classifications
a month ago
by
Zachary Nelson, PharmD, MPH, BCIDP(+1 more)
Why Piperacillin-Tazobactam for ESBL Still Needs Dose Optimization Data
1:08
Why Piperacillin-Tazobactam for ESBL Still Needs Dose Optimization Data
a month ago
by
Jason M. Pogue, PharmD, BCPS, BCIDP(+1 more)
Carbapenem-First Therapy For ESBL-Producing Organisms?
2:06
Carbapenem-First Therapy For ESBL-Producing Organisms?
a month ago
by
Jason M. Pogue, PharmD, BCPS, BCIDP(+1 more)
Ceftriaxone Resistance in Gonorrhea Underscores Need for Diversified Regimens
0:47
Ceftriaxone Resistance in Gonorrhea Underscores Need for Diversified Regimens
3 months ago
by
Lao-Tzu Allan-Blitz, MD, MPH(+1 more)
DOTS Trial Data Support Dalbavancin As an Option for Staph bacteremia
1:11
DOTS Trial Data Support Dalbavancin As an Option for Staph bacteremia
4 months ago
by
Megan E. Klatt, PharmD, BCIDP, DPLA (+1 more)
PeterPEN Data Could Bring Piperacillin-Tazobactam Back
1:37
PeterPEN Data Could Bring Piperacillin-Tazobactam Back
4 months ago
by
Megan E. Klatt, PharmD, BCIDP, DPLA (+1 more)
The Pressing Need for Antibiotic Alternatives
0:15
The Pressing Need for Antibiotic Alternatives
5 months ago
by
Jesus Rosado-Lugo, PhD(+1 more)
The Human and Financial Toll of C diff Recurrence
1:21
The Human and Financial Toll of C diff Recurrence
6 months ago
by
Christian John Lillis(+1 more)
Next Generation of AI is Better for Antibiotic Development
0:48
Next Generation of AI is Better for Antibiotic Development
7 months ago
by
Akhila Kosaraju, MD(+1 more)

Podcasts


CME Content


More News

A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.

The expanding gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems that each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.